Janux Therapeutics JANX Capital Lease Obligations Incurred
Capital Lease Obligations Incurred at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CapitalLeaseObligationsIncurred.
The official record: Janux Therapeutics’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's capital lease obligations incurred.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Janux Therapeutics's capital lease obligations incurred?
- Janux Therapeutics (JANX) reported capital lease obligations incurred of $235.75K in Q4 2025.
- What does capital lease obligations incurred mean?
- This represents the total value of new capital lease obligations entered into by the company during the reporting period. It indicates the company's reliance on leasing rather than purchasing assets to support its operations, such as laboratory equipment or facilities. Monitoring this is essential for understanding the company's off-balance-sheet financing and long-term fixed obligation profile.